Comparison between tenofovir alafenamide and entecavir in the efficacy and safety for chronic hepatitis B patients treatment.

Comparison between tenofovir alafenamide and entecavir in the efficacy and safety for chronic hepatitis B patients treatment. - Comparison between tenofovir alafenamide and entecavir in the efficacy and safety for chronic hepatitis B patients treatment.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026465

Enrollment

Registered

2017-04-01

Start date

2017-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with hepatitis B virus genotype C

Interventions

tenofovir alafenamide entecavir

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with hepatitis B virus genotype C

Exclusion criteria

Exclusion criteria: Patients with the past history of hypersensitivity against biologicals such as vaccine. Patients using Sho-saiko-to at present Autoimmune disease patients Patients with the past history of hypersensitivity against TAF and/or Entecavir

Design outcomes

Primary

Measure	Time frame
The decrease of cccDNA levels in the liver at 48 weeks after the treatment.	—

Countries

Japan

Contacts

Public ContactSatoru Hagiwara

Kindai University Faculty of Medicine Department of Gastroenterology and Hepatology

hagi-318@hotmail.co.jp072-366-0221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026